<?xml version="1.0" encoding="UTF-8"?>
<p id="Par37">Appropriate studies of pathogen reduction for labile blood products have not been published for either Nipah or Hendra, but similar viruses (i.e., enveloped RNA viruses) are effectively inactivated by the processes being advanced for approval in the United States. Likewise, one would expect that one or more of the s pecific viral inactivation, removal and purification steps in commercial plasma fractionation processes, would eliminate risk from derivatives.</p>
